Skip to main content

Advertisement

Table 2 Quality of Life, Medication Satisfaction, and Tolerability Scores

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

Quality of life instruments Baseline Change from baseline to week 4 Change from baseline to week 12
  Mean (SD) Mean (SD) P-value Mean (SD) P-value
*Physical health summary score (PHS) 48.2 (11.5) 0.015 ± 9.00 0.97 0.315 ± 9.20 0.79
*Mental health summary score (MHS) 50.7 (12.0) 0.366 ± 9.07 0.74 0.313 ± 10.01 0.81
*Augmented symptom distress module (ASDM) 26.7 (19.8) -2.99 ± 16.34 0.14 -2.92 ± 16.48 0.17
*Center for Epidemiology Studies-Depression (CES-D) 14.5 (10.2) -1.12 ± 8.00 0.25 -0.753 ± 8.47 0.49
   Mean value at week 4 Mean value at week 12
Medication satisfaction survey (MSS)   9.01 ± 2.27 NA 8.69 ± 2.25 NA
Global Condition improvement (GCI)   2.24 ± 3.05 <0.0001 2.46 ± 3.30 <0.0001
Therapy preference      
   Prefer LPV/r tablet [No. (%)]   55 (78%) <0.0001 46 (74%) <0.0001
   Prefer LPV/r SGC [No. (%)]   6 (9%)   6 (10%)  
   No preference [No. (%)]   9 (13%)   10 (16%)  
  1. *These instruments were scored according to the published scoring algorithm [46]; SD, standard deviation; SGC, soft gel capsule; LPV/r, lopinavir/ritonavir;